DOCSLIB.ORG

Quantity Level Limits on Prescription Drugs Policy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quantity Level Limits on Prescription Drugs Policy Pharmacy Policy Bulletin Category: Quantity Level Limits Number: J-6 Subject: Quantity Level Limits on Prescription Drugs Effective Date Begin: May 19, 2010 Effective Date End: Original Date: February 4, 2000 Review Date(s): May 19, 2010 March 3, 2010 March 4, 2009 December 3, 2008 September 3, 2008 May 21, 2008 December 5, 2007 September 5, 2007 May 16, 2007 December 6, 2006 Informational Policy Policy Applies to: Commercial plans only The following table contains a list of medications and the corresponding quantity level limits (number of units per prescription) that will be applied when members receive these medications through their prescription drug benefit. Please note that each medication has both retail and mail-order quantity level limits. Quantity level limits are applied for a variety of reasons including: (1) to prevent the stockpiling of medication; (2) to promote adherence to an appropriate course of therapy for reasons of efficacy and safety; and (3) to prevent medication misuse or abuse. Up to 34 Days Supply 35-90 Days Supply Limit Brand Name Generic Name Limit (retail) (retail or mail) Actonel™ 35mg Risedronate 4 tablets 12 tablets Actonel™ w/calcium Risedronate 28 tablets 84 tablets Actonel™ 75 mg Risedronate 2 tablets 6 tablets Actonel™ 150 mg Risedronate 1 tablet 3 tablet Amitiza Lubiprostone 60 capsules 180 capsules AndroGel® pump Testosterone gel 4 pumps (2 packages) 12 pumps (6 packages) Boniva® Ibandronate 1 tablet 3 tablets Byetta™ Exenatide 1 pen 3 pens 1Caverject® Alprostadil 6 injections 18 injections 1Cialis® Tadalafil 6 tablets 18 tablets Cialis® Tadalafil 6 tablets 18 tablets 2Clomid®/Serophene® clomiphene Females only Females only CombiPatch® Estradiol/norethindrone 8 patches 24 patches Cordran® Tape Flurandrenolide tape 2 tapes 6 tapes Diastat® Rectal Gel Diazepam rectal gel 2 prefilled applicators 2 prefilled applicators 1Edex® Alprostadil 6 injections 18 injections Emend® (80mg, 125mg) Aprepitant 3 capsules 3 capsules Emend® (40mg) Aprepitant 1 capsule 1 capsule EpiPen® Epinephrine 2 devices 2 devices Evoclin® Clindamycin foam 1-100g or 2-50g containers 3-100g or 6-50g containers Forteo® Teriparatide 1 multi-dose pen 3 multi-dose pens Calcitonin salmon Nasal Fortical Nasal Spray 1 bottle 3 bottles Spray Fosamax® 35 mg and 70 mg Alendronate 4 tablets 12 tablets Fosamax® plus D Alendronate 4 tablets 12 tablets Four (4) 75ml single use Twelve (12) 75ml single use Fosamax® oral solution Alendronate bottles bottles Gelnique™ Oxybutynin Gel 30 sachets 90 sachets GlucaGen® HypoKit™ Glucagon 1 kit 1 kit Glucagon Emergency Kit™ Glucagon 1 kit 1 kit 1Levitra® Vardenafil 6 tablets 18 tablets Levonorgestrel/ethinyl 1 extended-cycle tablet 1 extended-cycle tablet 6LoSeasonique® estradiol dispenser dispenser 3Lotronex® Alosetron 60 tablets 180 tablets Miacalcin® Nasal Spray Calcitonin Nasal Spray 1 bottle 3 bottles 1Muse® Alprostadil 6 suppositories 18 suppositories Cyanocobalamin Intranasal Nascobal Intranasal Spray 1 – 5ml bottle 2 – 5ml bottles Spray Nascobal Gel Cyanocobalamin 1 bottle 2 bottles Etonogestrel / ethinyl NuvaRing® 1 vaginal ring 3 vaginal ring estradiol Norelgestromin / ethinyl Ortho Evra™ 3 patches 9 patches estradiol Oxybutynin Transdermal Oxytrol™ 8 patches 24 patches System 4Plan B® Levonorgestrel 1 kit 1 kit Prozac Weekly® 90mg Delayed Release Fluoxetine 4 capsules 12 capsules Capsules 5Relenza® Zanamivir 1 Diskhaler and 5 Rotadisks 1 Diskhaler and 5 Rotadisks Granisetron transdermal Sancuso® 3 patches 3 patches system Levonorgestrel/ethinyl 1 extended-cycle tablet 1 extended-cycle tablet 6Seasonale® estradiol dispenser dispenser Seasonale® estradiol dispenser dispenser Levonorgestrel/ethinyl 1 extended-cycle tablet 1 extended-cycle tablet 6Seasonique™ estradiol dispenser dispenser Butorphanol tartrate Nasal Stadol® Nasal Spray 1 inhaler 3 inhalers Spray Ten 75mg capsules (5 days Ten 75mg capsules (5 days 7Tamiflu™ Oseltamivir supply) supply) Toradol® Ketorolac tromethamine 20 tablets 20 tablets Twinject® Epinephrine 2 devices 2 devices 1Viagra® Sildenafil 6 tablets 18 tablets liraglutide [rDNA origin] Victoza® 3 pens 9 pens injection Xifaxan rifaximin 9 (200mg) tablets 9 (200mg) tablets Zolpimist Zolpidem oral spray 1 canister 1 canister Estrogen Therapy Alora® Estradiol 1 box (8 patches) 3 boxes (24 patches) Climara® Estradiol 1 box (4 patches) 3 boxes (12 patches) ClimaraPro™ Estradiol/levonorgestrel 1 box (4 patches) 3 boxes (12 patches) Elestrin™ Estradiol Gel 1 metered-pump 3 metered-pumps Esclim™ Estradiol 1 box (8 patches) 3 boxes (24 patches) Estraderm® Estradiol 1 box (8 patches) 3 boxes (24 patches) EstroGel® 93 gm Estradiol 1 metered-pump 2 metered-pumps EstroGel® 50 gm Estradiol 1 metered-pump 3 metered-pumps Estrasorb® Estradiol Topical Emulsion 1 carton (56 pouches) 3 cartons (168 pouches) Estring® Estradiol Vaginal Ring 1 vaginal ring 1 vaginal ring Evamist™ Estradiol transdermal spray 1 canister 3 canisters Femring® Estradiol Vaginal Ring 1 vaginal ring 1 vaginal ring Menostar® Estradiol 1 box (4 patches) 3 boxes (12 patches) Vivelle® Estradiol 1 box (8 patches) 3 boxes (24 patches) 1. These drugs may be excluded if the group excludes impotency coverage. When a benefit, coverage is limited to males ≥18 years of age at the limits listed above. The 6 tablets/injections per fill is coded under the QLL benefit and the 18 tablets/injections per 75 days is coded under the MRxC benefit. Related policy: MRxC J-304 2. Clomid®, Serophene® and the generic for both, clomiphene, may be excluded if the group excludes fertility coverage. 3. Lotronex® is covered for females ages 18 and over when used to treat irritable bowel syndrome. 4. Plan B® is available over-the-counter for females ≥18 years of age and is thus not covered; however Plan B® is Rx only for females <18 years and is a covered product. 5. Coverage for Relenza® is limited to a five day supply of 1 diskhaler and five rotadisks per copayment in patients 7 years or older. Additional treatment courses (1 diskhaler and five rotadisks) will require an additional copayment. 6. Coverage for LoSeasonique®, Seasonale® and Seasonique™ is limited to 1 Extended-Cycle Tablet Dispenser per 91 days. The Extended-Cycle Tablet Dispenser contains 3 blister packs containing a total of 91 tablets. Two packs contain 28 tablets each and the third pack contains 31 tablets. 7. Coverage for Tamiflu™ is limited to a five day supply of ten (10) 75mg capsules per copayment in patients 13 years or older. Additional treatment courses (ten 75mg capsules) will require an additional copayment. View Previous Versions [Version 021 of J-6] [Version 020 of J-6] [Version 019 of J-6] [Version 018 of J-6] [Version 017 of J-6] [Version 016 of J-6] [Version 015 of J-6] [Version 014 of J-6] [Version 013 of J-6] [Version 012 of J-6] [Version 011 of J-6] [Version 010 of J-6] [Version 009 of J-6] [Version 008 of J-6] [Version 007 of J-6] [Version 006 of J-6] [Version 005 of J-6] [Version 004 of J-6] [Version 003 of J-6] [Version 002 of J-6] [Version 001 of J-6] Pharmacy policies do not constitute medical advice, nor are they intended to govern physicians' prescribing or the practice of medicine. They are intended to reflect Highmark's coverage and reimbursement guidelines. Coverage may vary for individual members, based on the terms of the benefit contract. Highmark retains the right to review and update its pharmacy policy at its sole discretion. These guidelines are the proprietary information of Highmark. Any sale, copying or dissemination of the pharmacy policies is prohibited; however, limited copying of pharmacy policies is permitted for individual use..
Load more

Recommended publications
  • Ophthalmic Adverse Effects of Nasal Decongestants on an Experimental
    A RQUIVOS B RASILEIROS DE ORIGINAL ARTICLE Ophthalmic adverse effects of nasal decongestants on an experimental rat model Efeitos oftálmicos adversos de descongestionantes nasais em modelo experimental com ratos Ayse Ipek Akyuz Unsal1, Yesim Basal2, Serap Birincioglu3, Tolga Kocaturk1, Harun Cakmak1, Alparslan Unsal4, Gizem Cakiroz5, Nüket Eliyatkın6, Ozden Yukselen7, Buket Demirci5 1. Department of Ophthalmology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 2. Department of Otorhinolaringology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 3. Department of Pathology, Veterinary Faculty, Adnan Menderes University, Aydin, Turkey. 4. Department of Radiology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 5. Department of Medical Pharmacology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 6. Department of Medical Pathology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 7. Department of Pathology, Aydin State Hospital, Aydin, Turkey. ABSTRACT | Purpose: To investigate the potential effects of cause ophthalmic problems such as dry eyes, corneal edema, chronic exposure to a nasal decongestant and its excipients cataracts, retinal nerve fiber layer, and vascular damage in on ocular tissues using an experimental rat model. Methods: rats. Although these results were obtained from experimental Sixty adult male Wistar rats were randomized into six groups. animals, ophthalmologists should keep in mind the potential The first two groups were control (serum physiologic) and ophthalmic adverse effects of this medicine and/or its excipients Otrivine® groups. The remaining four groups received the and exercise caution with drugs containing xylometazoline, Otrivine excipients xylometazoline, benzalkonium chloride, ethylene diamine tetra acetic acid, benzalkonium chloride and sorbitol, and ethylene diamine tetra acetic acid. Medications sorbitol for patients with underlying ocular problems.
    [Show full text]
  • Fee-For-Service Preferred Drug List
    Prescription Drug Program Apple Health Medicaid: Fee-for-Service Preferred Drug List What is new in this version of the preferred drug list? Effective for dates of service on and after October 1, 2018, the Health Care Authority will make the following changes: Change Due to the implementation of the Apple Health Preferred Drug List (PDL), a PDL that applies to fee-for-service (FFS) clients as well as Apple Health managed care enrollees, the following changes have occurred: On the Fee-For-Service only Preferred Drug List • Drug classes that are currently on the Apple Health PDL have been removed. These classes and the drug statuses can be found on the Apple Health Preferred Drug List. On the Apple Health Preferred Drug List • New drug classes have been added. This means drugs not previously on the PDL have been added with preferred and nonpreferred statuses. Some drugs may also have additional prior authorization (PA) requirements. • For existing drug classes, preferred statuses may have changed. Some drugs may have additional PA requirements that did not previously require PA. October 25, 2018 Correction • Two drug classes were erroneously removed and have been added back to the list: Asthma – Leukotriene Modifiers Skeletal Muscle Relaxants (Rev. 10/24/2018) (Eff. 10/1/2018) – 1 – Apple Health Medicaid PDL Prescription Drug Program What is the preferred drug list? The Health Care Authority (the agency) has developed a list of preferred drugs within a chosen therapeutic class that are selected based on clinical evidence of safety, efficacy, and effectiveness. The drugs within a chosen therapeutic class are evaluated by the Drug Use Review Board, which makes recommendations to the agency regarding the selection of the preferred drugs.
    [Show full text]
  • Study Protocol
    RESEARCH PROTOCOL Project Title A multicenter, single blind, randomized controlled trial of virucidal effect of Polyvinylpyrrolidone-Iodine on SARS-CoV-2 as well as safety of its application on nasopharynx & oropharynx of COVID-19 positive patients BMRC Reg. No: 38624012021 Page-1/17 Project Title A multicenter, single blind, randomized controlled trial of virucidal effect of Polyvinylpyrrolidone- Iodine on SARS-CoV-2 as well as safety of its application on nasopharynx & oropharynx of COVID- 19 positive patients. Summary Povidone Iodine (Iodine with water soluble polymer Polyvinylpyrolidone) or PVP-I is a proven and time trusted antiseptic agent having best possible (99.99%) virucidal effect in it‟s only 0.23% concentration, against all viruses including SARS-Co, MERS-CoV; even in SARS-COV-2 due to it‟s nonspecific mode of action for virus killing and having no resistance [1,2]. Corona virus is transmitted by/via respiratory droplets or aerosol, produced from sneezing or coughing of infected persons to healthy individual through mouth and nose mainly [5, 6]. The routes of entry of coronavirus in human body are mouth, nose and eye. PVP-I products for gargling the throat and spraying or washing the nose may have a preventive effect on COVID-19 and if it is proved in this study following human trial, this will be a landmark research in COVID-19 pandemic. In line of this, PVP-I containing oro-nasal spray, proposed Bangasafe, which should be regarded as PONS (Povidone Iodine oro-nasal spray) in this protocol, has been developed and proposed to use against corona virus disease.
    [Show full text]
  • Drug Delivery Technology Y
    * DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries.
    [Show full text]
  • Topical Management of Chronic Rhinosinusitis
    Open Access Advanced Treatments in ENT Disorders Review Article Topical Management of chronic rhinosinusitis - A literature review ISSN 1 2 2640-2777 Aremu Shuaib Kayode * and Tesleem Olayinka Orewole 1ENT Department, Federal Teaching Hospital, Ido-Ekiti/Afe Babalola University, Ado Ekiti, Nigeria 2Department of Anaesthesia, Federal Teaching Hospital, Ido Ekiti/Afe Babalola University, Ado Ekiti, Nigeria *Address for Correspondence: Dr. Aremu Shuaib Introduction Kayode, ENT Department, Federal Teaching Chronic rhinosinusitis (CRS) is an inlammatory condition involving nasal passages Hospital, Ido-Ekiti/Afe Babalola University, Ado Ekiti, Nigeria, Tel: +2348033583842; and the paranasal sinuses for 12 weeks or longer [1]. It can be subdivided into three Email: [email protected] types: CRS with nasal polyposis (CRS with NP), CRS without nasal polyposis (CRS Submitted: 08 April 2019 without NP), and Allergic fungal rhinosinusitis (AFRS). To diagnose CRS we require Approved: 25 April 2019 at least two of four of its cardinal signs/symptoms (nasal obstruction, mucopurulent Published: 26 April 2019 discharge, facial pain/pressure, and decreased sense of smell). In addition, direct Copyright: © 2019 Aremu SK, et al. This is visualization or imaging for objective documentation of mucosal inlammation is an open access article distributed under the required. CRS therapy is aimed to reduce its symptoms and improve quality of life as it Creative Commons Attribution License, which cannot be cured in most patients. Thus, the goals of its therapy include the following: permits unrestricted use, distribution, and reproduction in any medium, provided the 1: Control mucosal edema and inlammation of nasal and paranasal sinuses original work is properly cited 2: Maintain adequate sinus ventilation and drainage 3: Treat any infecting or colonizing micro-organisms, if present 4: Reduce the number of acute exacerbations Mucosal remodeling is the most likely underlying mechanism causing irreversible chronic sinus disease, similar to that occur in severe asthma.
    [Show full text]
  • 7.Inhalation Testing
    Analytical Challenges in Implementing Effective QC/Stability testing of Inhalation Drug Products Wayland Rushing, Ph.D. Director, Scientific Affairs Eurofins BioPharma Product Testing www.Eurofins.com Inhalation Overview Delivery of one or more drug products to the lungs or nasal mucosa Benefits: § Directly targets the lungs § Rapid onset of drug action • Quick absorption into bloodstream § Low doses required § Fewer side effects 2 Drug/Device Combination Devices Orally Inhaled and Nasal Drug Products (OINDP) § Metered Dose Inhaler (pMDI or simply MDI) • HFA propellant Driven § Dry Powder Inhaler (DPI) • Patient driven § Nebulizer • Aerosolizes solutions for constant delivery § Nasal Spray • Liquid or powder delivery to nasal cavity 3 Regulatory Guidance FDA Guidances § Guidance for Container Closure Systems for Packaging Human Drugs and Biologics (1999) § Reviewers Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators (1993) § Metered Dose Inhalers (MDI) and Dry Powder Inhalers (DPI) (revised 2018) § Nasal Spray and Inhalers Solution, Suspension, and Spray Drug Products (2002) § Drug Products Packaged in Semipermeable Container Closure Systems (2002) USP Chapters § USP <5>: Inhalation and Nasal Drug Products—General Information and Product Quality Tests § USP <601>: Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders— Performance Quality Tests § USP <1602>: Spacers and Valved Holding Chambers Used with Inhalation Aerosols— Characterization Tests § USP <1664.1>: Orally Inhaled and Nasal Drug Products 4 Revise
    [Show full text]
  • Nasal and Sinus Surgery After Care
    ENT SURGICAL CONSULTANTS 2201 Glenwood Ave., Joliet, IL 60435 (815) 725-1191, (815) 725-1248 fax Michael G. Gartlan, MD, FAAP, FACS 1890 Silver Cross Blvd, Pavilion A, Suite 435, New Lenox, IL 60451 Rajeev H. Mehta, MD, FACS 815-717-8768 Scott W. DiVenere, MD Sung J. Chung, MD 900 W. Rte 6, Suite 960., Morris, IL 60450 (815) 941-1972 Ankit M. Patel, MD Walter G. Rooney, MD www.entsurgicalillinois.com NASAL & SINUS SURGERY (7/13) Nasal Drainage and Bleeding Immediately after surgery, you will have drainage from your nose. At first, there may be a small amount of bright red bleeding, but do not be alarmed. A small amount is normal and may continue through the first week. A gauze dressing will be place on your upper lip to absorb this drainage. It may be necessary to change this dressing several times on the day of your surgery. Any bright red bleeding that lasts more than ten minutes, orEar, is heavy, Nose &spray Throat two Diseases puffs of over-the-counter Afrin decongestant nasal spray (or generic equivalent) in each nostril every ten minutesOtolaryngology until the bleeding-Head & subsides. Neck Surgery This should only be used for active bleeding. This medication is available. Facial Plastic & Reconstructive Surgery Relax with your head elevated,Thyroid tilt your and headParathyroid forward Surgery and gently pinch your nostrils with an ice pack over the bridge of your nose. Persistent bleeding should be reportedPediatric to Otolaryngologyyour doctor immediately. Old blood, which accumulated during surgery, is dark reddish-brown and will drain for a week or more.
    [Show full text]
  • FLONASE (Fluticasone Propionate) Nasal Spray Bacterial, Viral, Or Parasitic Infection; Ocular Herpes Simplex)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, These highlights do not include all the information needed to use contact dermatitis, rash) have been reported after administration of FLONASE safely and effectively. See full prescribing information for FLONASE nasal spray. Discontinue FLONASE nasal spray if such FLONASE. reactions occur. (5.3) • Potential worsening of infections (e.g., existing tuberculosis; fungal, FLONASE (fluticasone propionate) nasal spray bacterial, viral, or parasitic infection; ocular herpes simplex). Use with Initial U.S. Approval: 1994 caution in patients with these infections. More serious or even fatal course --------------------------- RECENT MAJOR CHANGES --------------------------- of chickenpox or measles can occur in susceptible patients. (5.4) • Hypercorticism and adrenal suppression may occur with very high Warnings and Precautions, Glaucoma and Cataracts (5.2) 1/2019 dosages or at the regular dosage in susceptible individuals. If such --------------------------- INDICATIONS AND USAGE ---------------------------- changes occur, discontinue FLONASE nasal spray slowly. (5.5) FLONASE nasal spray is a corticosteroid indicated for the management of the • Monitor growth of pediatric patients. (5.7) nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients ------------------------------ ADVERSE REACTIONS ------------------------------ aged 4 years and older. (1) The most common adverse reactions (>3%) are headache, pharyngitis, ----------------------- DOSAGE AND ADMINISTRATION ----------------------- epistaxis, nasal burning/nasal irritation, nausea/vomiting, asthma symptoms, For intranasal use only. Recommended starting dosages: and cough. (6.1) • Adults: 2 sprays per nostril once daily (200 mcg per day). (2.1) To report SUSPECTED ADVERSE REACTIONS, contact • Adolescents and children aged 4 years and older: 1 spray per nostril once GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or daily (100 mcg per day).
    [Show full text]
  • DDT Cover/Back April 2006.Qx
    June 2007 Vol 7 No 6 www.drugdeliverytech.com IN THIS ISSUE INTERVIEW WITH EURAND’S CHIEF COMMERCIAL OFFICER MR. JOHN FRAHER The eFlow® Nebulizer 30 Shabtai Bauer, PhD Markus Tservistas, PhD Bioadhesive Microspheres 54 Jayvadan Patel, PhD Transdermal Solutions 68 Gary W. Cleary, PhD FEATURING Imaging CROs 72 Richard Taranto Autoimmune The science & business of specialty pharma, biotechnology, and drug delivery Diseases 80 Douglas Kerr, MD Adam Kaplin, MD JuliaJulia Rashba-Rashba- Shaukat Ali, Richard Step,Step, PhDPhD PhD Sitz, MBA EfEfficientficient PulmonaryPulmonary HMW Povidone Beyond Sticky Partnering With DeliveryDelivery ofof BiologicalBiological PolymerPolymer-Based-Based toto Sophisticated:Sophisticated: NovaQuest 84 MoleculesMolecules asas Films for The Many PROMAXXPROMAXX Fast-Dissolving Dimensions Ms. Cindy H. Dubin MicrMicrospheresospheres Drug Delivery of Adhesives June 2007 Vol 7 No 6 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel:
    [Show full text]
  • Drug Delivery Technology
    * DDT Nov-Dec 2006 Round 5 11/10/06 7:20 PM Page 2 November/December 2006 Vol 6 No 10 IN THIS ISSUE Corporate Profiles 16 Drug Delivery Technologies 73 Excipients, Polymers, Liposomes & Lipids 90 Contract Pharmaceutical & Biological Development Services 96 Machinery & Laboratory Equipment and Software 109 Technology Spotlight 114 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 3 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 4 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 5 November/December 2006 Vol 6 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Fax: (703) 548-3733 E-mail: [email protected] E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] International Ralph Vitaro 219 Changebridge Road Vol 6 No 10 Montville, NJ 07045 Tel: (973) 299-1200 Fax: (973) 299-7937 E-mail: [email protected] Mailing List Rental Candy Brecht Tel: (703) 706-0383 Fax: (703) 549-6057 E-mail: [email protected] All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety November/December 2006 of artwork, photographs, or manuscripts.
    [Show full text]
  • Happy-Healthy-Hormones-Latest.Pdf
    HAPPY HEALTHY HORMONES Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE HAPPY HEALTHY HORMONES Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE This book has been written and published to provide information and should not be used as a substitute for the recommendations of your health care professional. Be- cause each person and medical situation are unique, the reader is urged to review this information with a qualified health professional. You should not consider the infor- mation contained in this text to represent the practice of medicine or to replace consultation with a physician or other qualifiedhealth care provider. The Menopause Method, Inc. Sarasota, Florida 941-366-3768 www.menopausemethod.com [email protected] The Menopause Method: A Woman’s Guide to Navigating Menopause, sixth edition, 2017. Copyright © 2001, 2002, 2006, 2007, 2014, 2017 by Daved Rosensweet M.D. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photo- copying, recording, or otherwise, without the prior written permission of the copyright owner. Sixth Edition 2017 ISBN: 9780999744901 Published in the United States of America Dedication This book is dedicated, first and foremost, to my patients in menopause: for 24 years, woman by woman, moment by moment, molecule by molecule, you have given me what has culminated in these pages. You know who you are, and I do thank you. Writing this dedication has turned out to be a deep and heartfelt experience for me.
    [Show full text]
  • Sodium Chloride | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Sodium Chloride This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US 4-Way Saline [OTC]; Afrin Saline Nasal Mist [OTC]; Altachlore [OTC]; Altamist Spray [OTC]; Atrapro Dermal Spray; Ayr Nasal Mist Allergy/Sinus [OTC]; Ayr Saline Nasal Drops [OTC]; Ayr Saline Nasal Gel [OTC]; Ayr Saline Nasal Neti Rinse [OTC]; Ayr Saline Nasal No-Drip [OTC]; AYR Saline Nasal Rinse [OTC]; Ayr Saline Nasal [OTC]; Ayr [OTC]; Baby Ayr Saline [OTC]; Deep Sea Nasal Spray [OTC]; DiaB Klenz [OTC] [DSC]; Entsol Nasal [OTC]; Humist [OTC] [DSC]; HyperSal; Liquivida Hydration [DSC]; MicroKlenz Wound Cleanser [OTC] [DSC]; Muro 128 [OTC]; Na- Zone [OTC] [DSC]; Nasal Moist [OTC]; Nebusal [DSC]; Ocean Complete Sinus Rinse [OTC]; Ocean for Kids [OTC]; Ocean Nasal Spray [OTC]; Ocean Ultra Saline Mist [OTC]; Pretz Irrigation [OTC]; Pretz Natur Moist Nasal Spray [OTC]; Pretz [OTC]; PulmoSal [DSC]; RadiaKlenz [OTC] [DSC]; Remedy 4-in-1 Body Cleanser [OTC] [DSC]; Rhinaris [OTC] [DSC]; Safe Wash [OTC]; Saline Flush ZR [DSC]; Saline Mist Spray [OTC]; Saljet Rinse [OTC]; Saljet [OTC]; Sea-Clens Wound Cleanser [OTC] [DSC]; Sochlor [OTC] [DSC]; SwabFlush Saline Flush [DSC]; Ultra- Klenz [OTC]; Wound Wash Saline [OTC] Brand Names: Canada Addipak Sodium Chloride; Aquapak; Ballard Unit Dose; Sodium Chlorure [DSC] Sodium Chloride 1/9 What is this drug used for? Injection and tablet: It is used to treat low sodium levels. Injection: It is used to treat fluid loss.
    [Show full text]